Bioinformatics Licensing Protein Expression 
Drug Discovery World
SEPTEMBER 25, 2024
Medilink’s $1 billion ADC licensing deal with Roche, signed in January 2024, also caught the eye, three months after a $1 billion deal ADC deal with BioNTech. Ries noted that there are other things to think about aside from finding targets expressed only on tumour cells. .”
Drug Target Review
APRIL 5, 2024
Together, these attributes provide a strong foundation for protein expression with enough adaptability to produce much of the commercial and therapeutic protein market.
Drug Discovery World
NOVEMBER 9, 2023
Peter O’Callaghan, PhD, Head of Expression System Sciences, Biologics and Licensing, Lonza, on: ‘Solve bispecific heavy-light chain mispairing with bYlok technology’.
Expert insights. Personalized for you.
162 
Let's personalize your content